RPRX
Royalty Pharma plc
Overview
Royalty Pharma plc acquires and manages royalties on biopharmaceutical products, receiving payments based on the top-line sales of approved therapies and development-stage candidates.
Royalty Pharma plc is a Healthcare company operating in Biotechnology with a $30.85B market cap.
Most recent reported earnings: Q2 FY2026 (Aug 4, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from SEC 10-K filing, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q1 FY2026Earnings2026-05-069 Q&A exchanges
- Q4 FY2025Earnings2026-02-1111 Q&A exchanges
- Q3 FY2025Earnings2025-11-057 Q&A exchanges
- Q2 FY2025Earnings2025-08-068 Q&A exchanges
- Q1 FY2025Earnings2025-05-088 Q&A exchanges
- Q4 FY2024Earnings2025-02-116 Q&A exchanges
- Q3 FY2024Earnings2024-11-068 Q&A exchanges
- Q2 FY2024Earnings2024-08-0815 Q&A exchanges
- Q1 FY2024Earnings2024-05-0910 Q&A exchanges
- Q4 FY2023Earnings2024-02-1513 Q&A exchanges
- Q3 FY2023Earnings2023-11-0811 Q&A exchanges
- Q2 FY2023Earnings2023-08-0810 Q&A exchanges
- Q1 FY2023Earnings2023-05-0915 Q&A exchanges
- Q4 FY2022Earnings2023-02-157 Q&A exchanges
- Q3 FY2022Earnings2022-11-0812 Q&A exchanges
- Q2 FY2022Earnings2022-08-0415 Q&A exchanges
- Q1 FY2022Earnings2022-05-0514 Q&A exchanges
- Q4 FY2021Earnings2022-02-1516 Q&A exchanges
- Q3 FY2021Earnings2021-11-1016 Q&A exchanges
- Q2 FY2021Earnings2021-08-1114 Q&A exchanges
- Q1 FY2021Earnings2021-05-1116 Q&A exchanges
History
Earnings history
- Q2 FY20262026-08-04EPS— vs $1.27—Rev— vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-04 | — | $1.27 | — | — | — | — | EODHD |
Source: EODHD. RPRX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks RPRX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 70% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.74 | $3.24 | +15.5% | -2.7% | -0.4% |
| Q4 FY2026 | $4.09 | $3.48 | +17.5% | +7.1% | +4.6% |
| Q3 FY2026 | $3.67 | $3.52 | +4.2% | +1.1% | +3.8% |
| Q2 FY2026 | $3.84 | $3.48 | +10.3% | -4.2% | -2.7% |
| Q1 FY2025 | $3.97 | $3.59 | +10.5% | +0.7% | -2.3% |
| Q4 FY2025 | $3.79 | $3.53 | +7.5% | +2.1% | +1.7% |
| Q3 FY2025 | $3.55 | $3.36 | +5.7% | +1.5% | -0.7% |
| Q2 FY2025 | $3.86 | $3.52 | +9.8% | +2.0% | +2.5% |
| Q1 FY2024 | $3.78 | $3.67 | +3.0% | -1.3% | -0.2% |
| Q4 FY2024 | $3.62 | $3.44 | +5.1% | +4.6% | +3.1% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Pablo G LegorretaCEO10 mo19 callsCurrentSample
CEO since 2025 • 2/4 beats (50%) • last guidance raise Q1 FY2026
- Terrance P CoyneCFO7 mo9 callsCurrentSample
CFO since 2025 • 3/4 beats (75%) • last guidance raise Q3 FY2026
- George W LloydEVP, Investments & CLO7 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 2/4 beats (50%) • guidance suspended Q3 FY2026
- Arthur Richard McGivernEVP, Investments & GC5 mono recorded callsCurrentSample
DIVISION_HEAD since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
- Christopher HiteEVP & Vice Chairman7 mo19 callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
- Marshall UristEVP, Research & Investments7 mo20 callsCurrentSample
DIVISION_HEAD since 2025 • 2/4 beats (50%) • last call held guidance Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RPRX.
$ curl https://api.spokenalpha.com/v1/companies/RPRXFAQ
Frequently asked about RPRX
Where can I find Royalty Pharma plc's (RPRX) earnings call transcripts?
Spoken Alpha indexes RPRX's earnings call transcripts at https://spokenalpha.com/companies/RPRX. Each call links to attributed speakers and parsed analyst Q&A. Royalty Pharma plc's own investor relations page is at https://www.royaltypharma.com/investors/.
When was Royalty Pharma plc's most recent earnings call?
Royalty Pharma plc (RPRX) held its most recent earnings call on 2026-05-06, covering fiscal Q1 2026.
What sector is RPRX in?
Royalty Pharma plc (RPRX) operates in the Healthcare sector (Biotechnology industry).